Fasting Blood Ammonia Predicts Risk and Frequency of XXXX Episodes in @entity1 With @entity82 .

@entity1 @entity82 @entity3265 @entity3655 @entity99 @entity72656
BACKGROUND _ AIMS: There is controversy over the use of measuring blood levels of @entity3265 ( @entity3655 ) in the management of @entity1 with overt @entity99 ( @entity99 ). METHODS: We performed a retrospective analysis of data from a randomized, double-blind study of 178 @entity1 with @entity82 given @entity72656 (an @entity3655 -lowering agent) or placebo for 16 weeks. Blood samples were collected at baseline and on study days 7 and 14 and @entity3655 levels were measured. The probabilities of having an @entity99 episode, based on ammonia values, were modeled using binary logistic regression. A Cox proportional model was used to determine the risk of @entity99 episodes in @entity1 with baseline fasting @entity3655 levels  <=1.5-fold the upper limit of normal (ULN) versus @entity1 with fasting @entity3655 levels >1.5-fold the ULN. RESULTS: The risk and frequency of @entity99 episodes and @entity99 -related hospitalizations correlated with baseline (mean, 51    6  mol/L; ULN, 35  mol/L) and on-study fasting levels of @entity3655 , and increased sharply at levels >1.5-fold the ULN. Regardless of baseline level, @entity3655 exposure and the relative risk of @entity99 episodes were decreased by @entity72656 . CONCLUSIONS: In analysis of data from a phase 2 study of the effects of @entity72656 in @entity1 with @entity82 , we found that fasting levels of @entity3655 in blood can identify @entity1 at risk for @entity99 -related morbidity. @entity1 with @entity99 might benefit from @entity3655 -lowering therapy. ClinicalTrials.gov no: NCT  00999167.
